An open-label, multicenter study to evaluate yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen

被引:127
|
作者
Parsey, KS [1 ]
Pong, A [1 ]
机构
[1] Berlex Labs, Montville, NJ 07045 USA
关键词
Yasmin; drospirenone; oral contraceptive; ethinyl estradiol; efficacy; cycle control; menstrual distress questionnaire;
D O I
10.1016/S0010-7824(00)00083-4
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
This open-label, multicenter study evaluated the efficacy, safety, and cycle control of Yasmin, a new low-dose, monophasic oral contraceptive containing the unique progestogen drospirenone (DRSP) 3 mg and ethinyl estradiol (EE) 30 mu g. DRSP is a synthetic progestogen that has antiandrogenic and antimineralocorticoid effects. In this study, 326 women were evaluated and 220 (67%) completed all 13 treatment cycles. The corrected Pearl Index was 0.407. Of the 151 subjects who experienced intermenstrual bleeding at any time during the study, the majority (64%) had bleeding during only one or two pill cycles. Breakthrough bleeding without spotting occurred in 1% of all cycles, spotting without breakthrough bleeding in 9.3% of all cycles, and breakthrough bleeding with spotting in 3% of all cycles. Amenorrhea was observed in 3% of all cycles. In all, 20 subjects (6%) discontinued participation in the study because of adverse events. No serious adverse events related to the study drug were reported. No clinically significant changes in weight, blood pressure, or lipids were reported. The impact of the new progestogen DRSP on the women's self-perception of menstrual health was also evaluated. Subjects reported that symptoms of water retention, negative affect, and increased appetite significantly improved at cycle 6 from baseline. This study demonstrates that Yasmin is an effective oral contraceptive that is safe and well tolerated. (C) 2000 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:105 / 111
页数:7
相关论文
共 50 条
  • [21] A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation
    Kroll, Robin
    Seidman, Larry
    Ricciotti, Nancy
    Howard, Brandon
    Weiss, Herman
    EUROPEAN JOURNAL OF CONTRACEPTION AND REPRODUCTIVE HEALTH CARE, 2015, 20 (04): : 249 - 258
  • [22] A STUDY OF INTERACTION OF LOW-DOSE COMBINATION ORAL-CONTRACEPTIVE WITH AMPICILLIN AND METRONIDAZOLE
    JOSHI, JV
    JOSHI, UM
    SANKHOLI, GM
    KRISHNA, U
    MANDLEKAR, A
    CHOWDHURY, V
    HAZARI, K
    GUPTA, K
    SHETH, UK
    SAXENA, BN
    CONTRACEPTION, 1980, 22 (06) : 643 - 652
  • [23] Hemostatic effects of two desogestrel-containing combined oral contraceptive regimens: a multinational, multicenter, randomized, open-label study
    Peters, K.
    Gordon, N.
    Ricciotti, N.
    Hsieh, J.
    Howards, B.
    Weiss, H.
    CLINICAL AND EXPERIMENTAL OBSTETRICS & GYNECOLOGY, 2016, 43 (03): : 334 - 340
  • [24] EFFECT OF A LOW-DOSE ESTROGEN-PROGESTOGEN ORAL-CONTRACEPTIVE ON LIPIDS AND LIPOPROTEINS
    TAGGART, H
    STOUT, RW
    IRISH JOURNAL OF MEDICAL SCIENCE, 1981, 150 (01) : 13 - 14
  • [25] Effects of low dose oral contraceptive pill containing drospirenone/ethinylestradiol in patients with endometrioma
    Taniguchi, Fuminori
    Enatsu, Akiko
    Ota, Ikuko
    Toda, Toshiko
    Arata, Kazuya
    Harada, Tasuku
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2015, 191 : 116 - 120
  • [26] Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata
    Eisinger, Steve H.
    Fiscella, Julietta
    Bonfiglio, Thomas
    Meldrum, Sean
    Fiscella, Kevin
    EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY, 2009, 146 (02) : 215 - 218
  • [27] Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study
    Thomas Paparrigopoulos
    Elias Tzavellas
    Dimitris Karaiskos
    Georgia Kourlaba
    Ioannis Liappas
    BMC Psychiatry, 11
  • [28] Treatment of alcohol dependence with low-dose topiramate: an open-label controlled study
    Paparrigopoulos, Thomas
    Tzavellas, Elias
    Karaiskos, Dimitris
    Kourlaba, Georgia
    Liappas, Ioannis
    BMC PSYCHIATRY, 2011, 11
  • [29] The impact of a new low dose oral contraceptive containing drospirenone on lipid profile, carbohydrate metabolism and hepatic function
    Szlendak-Sauer, Katarzyna
    Radowicki, Stanislaw
    Skorzewska, Katarzyna
    GINEKOLOGIA POLSKA, 2009, 80 (02) : 99 - 102
  • [30] HEMOSTATIC EFFECTS OF TWO ORAL CONTRACEPTIVE REGIMENS: A MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY.
    Ricciotti, N.
    Howard, B.
    Weiss, H.
    FERTILITY AND STERILITY, 2013, 100 (03) : S313 - S313